Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 193, Issue 1-2, Pages 113-119Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2007.10.023
Keywords
beta-adrenergic; testosterone; sex differences; MADB106
Categories
Funding
- NCI NIH HHS [R01 CA073056-05, R01 CA073056, CA73056] Funding Source: Medline
- NINR NIH HHS [NR07742, R01 NR007742-05, R01 NR007742] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA073056] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR007742] Funding Source: NIH RePORTER
Ask authors/readers for more resources
We studied the development of sexual dimorphism in resistance to NK-sensitive experimental metastasis under baseline conditions and following adrenoceptor stimulation. With increasing age, baseline resistance to MADB 106 lung tumor retention (LTR) increased in both sexes, but also the susceptibility to the tumor-enhancing effects of a beta-adrenergic agonist, metaproterenol. Beginning at 13 weeks, males exhibited a 2- to 3-fold greater increase in LTR than females following adrenoceptor stimulation. This adult dimorphism was robust to ovariectomy, and questionably related to androgens. The findings are consistent with reduced female responsiveness to sympathetic activation, and substantiate the importance of including both sexes when studying neuroimmunomodulation. (C) 2007 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available